Isotechnika Pharma Inc IPHAF

RE: RE: RE: RE: RE: Re: Goldman

[ngerrits]

I agree that taking over ISA is probably an excellent strategy for Lux given the milestone payments are a little less than the the actual mkt cap of ISA and they get a listing, etc.  Foster would likely not be part of the new Co. which could be a deal breaker as he likely wants to physically see this drug prescribed by doctors before he exits.

My concern is how our biggest shareholder's - 3SBIO & Palidan will react and at what price they would be willing to part with their shares.  They presumably bought into ISA for the drug itself, not on M&A speculation.  (maybe even tax losses)

I think the market would give us a premium towards 0.50 if there was sense that we may be bought outright.

Everyone has to start looking at ISA as a holdco, whose value is determined by Lux, 3Sbio, and Palidan now.  Future licensing deals aside, these 3 co's and the way they decide how voclo fits into their LT strategies will determine how high ISA shares will go.

Just one shareholder's opinion.